Aspergillosis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 90 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Aspergillosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Aspergillosis - Pipeline Review, H2 2014', provides an overview of the Aspergillosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aspergillosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Aspergillosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Aspergillosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Aspergillosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Aspergillosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Aspergillosis Overview 9
Therapeutics Development 10
Pipeline Products for Aspergillosis - Overview 10
Pipeline Products for Aspergillosis - Comparative Analysis 11
Aspergillosis - Therapeutics under Development by Companies 12
Aspergillosis - Therapeutics under Investigation by Universities/Institutes 14
Aspergillosis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Aspergillosis - Products under Development by Companies 18
Aspergillosis - Products under Investigation by Universities/Institutes 19
Aspergillosis - Companies Involved in Therapeutics Development 20
Amplyx Pharmaceuticals, Inc. 20
Astellas Pharma Inc. 21
Aureogen Biosciences, Inc. 22
Basilea Pharmaceutica AG 23
Biomar Microbial Technologies 24
Eisai Co., Ltd. 25
F2G Ltd 26
iCo Therapeutics Inc. 27
MABLife S.A.S 28
Merck & Co., Inc. 29
Novabiotics Ltd 30
Pulmocide Ltd 31
Sealife PHARMA GMBH 32
Sigma-Tau S.p.A. 33
Aspergillosis - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
amphotericin b - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
amphotericin b NanoDisk - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ASP-2397 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ASP-9726 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AUGC-10 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AUGC-15 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
E-1210 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
E-1211 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
F-901318 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
FK506 Analogues - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
isavuconazonium sulfate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KB-425796C - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MAT-401 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MDN-0018 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NP-339 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
posaconazole - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PTX-3 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SLP-0901 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SLP-0904 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules for Fungal Infections - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules for Fungal Infections - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Invasive Pulmonary Aspergillosis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Inhibit ATP-Binding Cassette (ABC) Superfamily for Fungal Infections - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Aspergillosis - Recent Pipeline Updates 70
Aspergillosis - Dormant Projects 76
Aspergillosis - Discontinued Products 77
Aspergillosis - Product Development Milestones 78
Featured News & Press Releases 78
Sep 06, 2014: Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 78
Sep 05, 2014: Astellas to Showcase Isavuconazole Data at ICAAC 78
Sep 05, 2014: Extensive data presented on Basilea's anti-infectives isavuconazole at ICAAC 80
Sep 02, 2014: F2G announces commencement of a Phase 1 single ascending dose study of a novel antifungal agent, F901318 83
Aug 21, 2014: European Medicines Agency Accepts Basilea's isavuconazole Marketing Authorization Application For Review 83
Jul 30, 2014: CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Merck's NOXAFIL (posaconazole) 84
Jul 14, 2014: Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections 84
Jul 09, 2014: Astellas Submits U.S. New Drug Application for Isavuconazole for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 85
May 14, 2014: Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID 86
Mar 17, 2014: Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL Injection for Intravenous Use, a New Captisol-enabled Formulation 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Tables
Number of Products under Development for Aspergillosis, H2 2014 10
Number of Products under Development for Aspergillosis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2014 20
Aspergillosis - Pipeline by Astellas Pharma Inc., H2 2014 21
Aspergillosis - Pipeline by Aureogen Biosciences, Inc., H2 2014 22
Aspergillosis - Pipeline by Basilea Pharmaceutica AG, H2 2014 23
Aspergillosis - Pipeline by Biomar Microbial Technologies, H2 2014 24
Aspergillosis - Pipeline by Eisai Co., Ltd., H2 2014 25
Aspergillosis - Pipeline by F2G Ltd, H2 2014 26
Aspergillosis - Pipeline by iCo Therapeutics Inc., H2 2014 27
Aspergillosis - Pipeline by MABLife S.A.S, H2 2014 28
Aspergillosis - Pipeline by Merck & Co., Inc., H2 2014 29
Aspergillosis - Pipeline by Novabiotics Ltd, H2 2014 30
Aspergillosis - Pipeline by Pulmocide Ltd, H2 2014 31
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2014 32
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 36
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Aspergillosis Therapeutics - Recent Pipeline Updates, H2 2014 70
Aspergillosis - Dormant Projects, H2 2014 76
Aspergillosis - Discontinued Products, H2 2014 77